A Phase 3 interventional study of Low dose ASA and High dose ASA in Migraine Disorders, sponsored by Boehringer Ingelheim. Completed. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2014-07-08.
Sponsored by Boehringer Ingelheim · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies testing acetaminophen in Migraine Disorders — 1 open to participants now, 1 under way, none of them phase 3. Acetaminophen · Migraine Disorders.
Among the 15 studies testing acetaminophen in Migraine Disorders, this one has the largest enrollment, is the only one that started in 1998, is one of 3 in phase 3, and was the 6th registered.
1,658 studies on the registry are indexed under Migraine Disorders; 340 are open to participants now.
Browse Migraine Disorders studies →1 of the 15 studies testing acetaminophen in Migraine Disorders is open now, in 1 country. Recruiting first, the newest first:
University of Monastir · Sites in Tunisia
Ages 18+
By country, each count listing its studies:
Acetaminophen: first FDA approval 1968 (NEOPAP). What it is approved for, and how studies give it, is on its page →
Of the 217 Migraine Disorders studies recruiting now, 66 (30%) set no upper age limit and 136 (63%) stop at 75 or younger; 44 take children under 18; 37 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 5 · Phase 3 4 · Phase 4 5
First in 1998; this study’s year is marked. 1 started in 1998.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,889 is above the median of 80 across 1,269 interventional studies indexed under Migraine Disorders.
Median enrollment 200 across the 15 interventional studies. Of the 12 that completed or were terminated, 4 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 15 have an industry lead sponsor. The 9 most frequent:
Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.
Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.
Boehringer Ingelheim has 5 studies filed under Migraine Disorders — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 15 studies testing acetaminophen in Migraine Disorders, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To confirm the combination rationale for the combination of ASA + paracetamol + caffeine compared with the combination of ASA + paracetamol and the individual substances ASA, paracetamol, caffeine, and placebo administered orally to headache patients for two headache episodes
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Diagnosis: Headache
Exclusion Criteria:
Migraine prophylaxis or administration of drugs, indicated for any other reasons that influence headache symptoms, e.g.
Propanolol, Metoprolol, Flunarizine, Cyclandelate, Valproic acid, Serotonin antagonists (pizotifen, methysergide, lisuride), Ergotamine, Dihydroergotamine, Benzodiazepines, Magnesium, Monoamine oxidase inhibitors
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Low dose ASA · Drug: Low dose paracetamol · Drug: Caffeine
Drug: Low dose ASA · Drug: Low dose paracetamol
Drug: High dose ASA
Drug: High dose paracetamol
Drug: Caffeine
Drug: Placebo
Calculated time to 50% pain relief, based on the pain intensity evaluated on a visual analogue scale (VAS)
Time frame: 30 min., 1, 2, 3 and 4 hours after administration of the study medication
Percentage of patients with 50 % pain relief, evaluated on a VAS
Time frame: At least 2 hours after administration of the study medication
Percentage of patients with 50 % pain relief, evaluated on a VAS
Time frame: At least 30 min., 1, 3, and 4 hours after administration of the study medication
Pain intensity, evaluated on a VAS
Time frame: 30 min., 1, 2, 3 and 4 hours after administration of the study medication
Ratio of weighted sum of pain intensity difference scores to maximum achievable sum of pain intensity differences (%SPIDweighted), evaluated on a VAS
Time frame: Up to the end of the study
Extent of impairment of daily activities, evaluated on a 4-grade verbal scale (VRS)
Time frame: Before, 30 min., 1, 2, 3 and 4 hours after administration of study drug
Duration of headache
Time frame: Up to 48 hours after onset of each headache episode
Global assessment of efficacy by the patient, evaluated on a 4-grade VRS
Time frame: Within 12 hours after study drug administration
Global assessment of tolerability by the patient, evaluated on a 4-grade VRS
Time frame: Within 12 hours after study drug administration
Number of patients with adverse events
Time frame: Up to the end of the study
Global assessment of tolerability by the investigator, evaluated on a 4-grade VRS
Time frame: After each administration of study drug during the treatment phase
No study locations are listed for this record.
The record gives a start of Sep 1998 and a primary completion of Jan 2003. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Aspirin · Acetaminophen · Caffeine